Live Analyst Rating Changes 2174 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/William Plovanic
CG
William Plovanic
Wall Street Analyst
★★★☆☆
#1320
on 13Foresight · ranked by our own returns
56%
Success Rate
+6.3%
Average Return
20 of 36 calls profitable · -6.0% vs benchmark
📈 Across the calls we could measure, roughly 56% of William Plovanic's ratings turned a profit when each position was held for 1 year — averaging +6.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

129 Buy 11 Hold 0 Sell
William's Stock Coverage 37 ratings · 2026-06-24
Company Date Position Consensus Price Target 1-Yr Return
AORT
Artivion
Jun 16, 2026 BUY Strong Buy
+97.9% avg upside
8 analysts
$36.00
71.07% Upside
·
TMDX
TransMedics Group
Jun 09, 2026 BUY Strong Buy
+56.6% avg upside
15 analysts
$124.00
59.91% Upside
+6.1%
PLSE
Pulse Biosciences
Jun 04, 2026 BUY Strong Buy
+17.8% avg upside
5 analysts
$32.00
25.15% Upside
·
PEN
Penumbra
Jun 02, 2026 HOLD Buy
+4.5% avg upside
23 analysts
$374.00
18.08% Upside
-0.8%
IRTC
Irhythm Technologies
Jun 01, 2026 BUY Strong Buy
+56.7% avg upside
19 analysts
$152.00
45.92% Upside
·
BSX
Boston Scientific
Jun 01, 2026 BUY Strong Buy
+74.0% avg upside
38 analysts
$70.00
55.59% Upside
-5.6%
DXCM
Dexcom
May 19, 2026 BUY Strong Buy
+43.8% avg upside
32 analysts
$82.00
15.32% Upside
+2.9%
HTFL
HeartFlow, Inc.
May 15, 2026 BUY Strong Buy
+7.0% avg upside
8 analysts
$37.00
7.35% Upside
+18.8%
TLSI
TriSalus Life Sciences
May 13, 2026 BUY Strong Buy
+124.5% avg upside
8 analysts
$7.00
69.08% Upside
+0.4%
CBLL
Ceribell, Inc.
May 12, 2026 BUY Strong Buy
+36.1% avg upside
8 analysts
$25.00
37.51% Upside
+9.8%
CVRX
CVRx
May 12, 2026 BUY Strong Buy
+128.8% avg upside
9 analysts
$10.00
99.60% Upside
+15.9%
TNDM
Tandem Diabetes Care
May 08, 2026 BUY Buy
+128.8% avg upside
29 analysts
$35.00
128.79% Upside
-3.9%
PODD
Insulet
May 07, 2026 BUY Strong Buy
+82.4% avg upside
32 analysts
$249.00
73.51% Upside
-9.1%
ATEC
Alphatec Holdings
May 06, 2026 BUY Strong Buy
+117.9% avg upside
22 analysts
$23.00
157.36% Upside
+15.7%
ATRC
Atricure
May 06, 2026 BUY Strong Buy
+59.6% avg upside
12 analysts
$55.00
90.76% Upside
+0.4%
SYK
Stryker
May 01, 2026 BUY Strong Buy
+23.9% avg upside
36 analysts
$400.00
30.22% Upside
+2.2%
LUNG
Pulmonx
Apr 30, 2026 BUY Strong Buy
+322.3% avg upside
9 analysts
$5.00
296.74% Upside
+7.0%
EW
Edwards Lifesciences
Apr 24, 2026 HOLD Strong Buy
+12.8% avg upside
34 analysts
$85.00
2.05% Downside
+3.0%
STIM
Neuronetics
Apr 06, 2026 BUY Strong Buy
+391.6% avg upside
6 analysts
$3.00
138.13% Upside
-31.8%
SIBN
SI-Bone
Jan 22, 2024 BUY Strong Buy
+59.5% avg upside
18 analysts
$25.00
54.68% Upside
-13.8%
GMED
Globus Medical
Jan 22, 2024 BUY Strong Buy
+20.4% avg upside
24 analysts
$79.00
0.88% Upside
+66.5%
AXGN
AxoGen
Dec 21, 2023 BUY Strong Buy
-25.8% avg upside
21 analysts
$15.00
66.39% Downside
+118.7%
ANGO
AngioDynamics
Dec 21, 2023 BUY Strong Buy
+37.2% avg upside
9 analysts
$19.00
54.44% Upside
+14.4%
ZBH
Zimmer Biomet Holdings
Dec 15, 2023 HOLD Buy
+28.0% avg upside
37 analysts
$131.00
49.04% Upside
-9.3%
BVS
Bioventus
Dec 07, 2023 BUY Strong Buy
+35.6% avg upside
8 analysts
$7.00
20.77% Downside
+128.6%
SNN
Smith & Nephew Snats
Nov 30, 2023 HOLD Buy
+13.4% avg upside
14 analysts
$32.00
7.35% Upside
+2.2%
ENOV
Enovis
Nov 07, 2023 BUY Strong Buy
+226.1% avg upside
37 analysts
$65.00
201.52% Upside
-1.0%
STAA
Staar Surgical
Sep 15, 2023 HOLD Hold
+16.3% avg upside
16 analysts
$43.00
50.05% Upside
-25.3%
MMSI
Merit Medical Systems
Aug 28, 2023 HOLD Strong Buy
+35.8% avg upside
15 analysts
$70.00
5.06% Upside
+45.4%
AFIB
Acutus Medical
Aug 08, 2023 HOLD Sell
+619899.9% avg upside
5 analysts
$0.74
739899.93% Upside
·
OCGN
Ocugen
Feb 02, 2016 BUY Strong Buy
+578.9% avg upside
17 analysts
$8.00
522.49% Upside
-34.6%
MDXG
MiMedx Group
Jan 11, 2016 BUY Strong Buy
+180.5% avg upside
17 analysts
$12.00
224.39% Upside
+1.5%
LFWD
Lifeward
Nov 05, 2015 BUY Strong Buy
+4.3% avg upside
8 analysts
$16.00
128.55% Upside
-66.7%
GADS
Gadsden Prop
Feb 02, 2015 HOLD Buy
+8999900.1% avg upside
5 analysts
·
LIVN
LivaNova
Jun 05, 2014 BUY Strong Buy
+0.9% avg upside
14 analysts
$63.00
20.09% Downside
·
OFIX
Orthofix Medical
Sep 09, 2011 BUY Strong Buy
+214.1% avg upside
15 analysts
$45.00
378.30% Upside
+27.7%
IART
Integra Lifesciences
Jun 28, 2011 BUY Buy
+134.8% avg upside
21 analysts
-23.8%
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
William Plovanic — Frequently Asked Questions
How accurate are William Plovanic's stock ratings?
Based on the calls 13Foresight could measure, about 56% of William's ratings were profitable over a one-year hold, with an average return of +6.3% per rating, or -6.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is William ranked on 13Foresight?
William Plovanic is currently ranked #1320 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does William cover?
William most recently has ratings on AORT, TMDX, PLSE, PEN, IRTC, BSX, DXCM, HTFL, TLSI, CBLL, CVRX, TNDM and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.